Delivery Order SPE2DB22D2103-SPE2DB25FR9PD
- Not listed
- The Defense Logistics Agency (DLA) awarded a $1,629.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector pharmaceutical supplies, with an ultimate completion date of July 21, 2025. This non-set-aside competitively awarded contract represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,646.02 to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units on July 25, 2025, with completion scheduled for July 28, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitive award under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xyosted is a...
- The Defense Logistics Agency awarded a delivery order valued at $1,524.90 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector supplies on July 18, 2025, with completion targeted for July 21, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award based on capability. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical delivery order. This delivery order...
- The Defense Logistics Agency awarded a $3,155.07 delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector medication, with performance scheduled for completion by July 22, 2025. This non-competitive delivery order represents a firm fixed price contract executed on July 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $1,308.93 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector units on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy product administered via auto-injector, supporting the Defense Health...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of 100 mg/0.5 mL XYOSTED auto-injectors. The $1,309.95 order will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with a completion date of January 16, 2024. This delivery order was placed under an existing indefinite delivery contract between AmerisourceBergen Drug Corp and DLA to...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products. The total potential value of the delivery order is $1,452.66, with a completion date of March 7, 2024. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,703.83 firm fixed-price delivery order is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product, with a completion date of November 12, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- This is a $2,444.49 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product, with a period of performance through July 1, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed-price delivery order worth $1,539.05 to Amerisourcebergen Drug Corp's Corporate Office division located in Conshohocken, Pennsylvania. This order is for the pharmaceutical product XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML and has an ultimate completion date of April 10, 2024. Amerisourcebergen Drug Corp, a for-profit organization and subsidiary of Amerisourcebergen Corporation, is also the prime contractor on a...
- SPE2DB22D2103Indefinite Delivery Contract
- SPE2DB22D2103-SPE2DB25FR9PDDelivery Order
The Defense Logistics Agency awarded a $1,270.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The delivery order will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and primary distribution operations. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has established itself as a critical vendor for federal medical procurement through competitive awards and comprehensive product portfolios serving military and veteran healthcare systems. Xyosted is a testosterone replacement therapy delivered via auto-injector, representing the type of specialty pharmaceutical products the company supplies to support Defense Health Agency and broader DoD medical supply requirements. The delivery order demonstrates the flexibility and responsiveness of the underlying IDC vehicle in fulfilling specific pharmaceutical commodity needs for federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 7/25/25 |